SEATTLE, May 13, 2019 (GLOBE NEWSWIRE) — Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced financial results for the quarter ended March 31, 2019 and provided an update on recent company developments.
Steven C. Quay, M.D., Ph.D., Atossa Genetics’ President and CEO commented, “As we anticipated, we completed dosing in the topical Endoxifen breast density study in April and we look forward to announcing initial top-line results later this quarter. Further, as previously reported, the FDA approved an ‘Expanded Access’ program for use of our oral Endoxifen to treat a breast cancer patient prior to her surgery and in March 2019 we received a second approval for this patient to continue treatment post-surgery. We are planning a Phase 2 clinical study using our oral Endoxifen to reduce breast density and we look forward to providing updates on the launch of that study and progress with our other programs.”
Q1 2019 Corporate Developments
Developments during the first quarter include the following:
- April 2019 – Completed dosing of Phase 2 topical Endoxifen breast density trial
- April 2019 – Completed the first phase of a preclinical study using proprietary intraductal delivery technology. The company is now advancing to the next preclinical phase, which involves the intraductal administration of immune modulating formulations. These results will form the basis for advancing the intraductal delivery program into humans and to ultimately deliver immunotherapy to treat breast cancer using Atossa’s proprietary intraductal delivery technology
- March 2019 – FDA approval of oral Endoxifen for expanded access as post-mastectomy treatment for a U.S. breast cancer patient
- March 2019 – Atossa received $11.3 million from the exercise of warrants that were previously outstanding
- February 2019 – Atossa provided breast cancer prevention recommendations to the United States Preventative Services Task Force
- February 2019 – Atossa reports results from expanded access program for a U.S. breast cancer patient taking oral Endoxifen: sizeable reduction in cancer cell biological activity; no safety or tolerability issues
- January 2019 – Successfully completed and provided final results from male Phase 1 study of topical Endoxifen; no clinically significant safety nor tolerability issues and acceptable pharmacokinetics
Q1 2019 Financial Results
For the quarter ended March 31, 2019 the company reported no revenue and no associated cost of revenue.
Total operating expenses were approximately $4,064,000 for the three months ended March 31, 2019, which is an increase of approximately $2,190,000 or 117 percent, from the three months ended March 31, 2018. Operating expenses for the three months ended March 31, 2019 consisted of research and development (R&D) expenses of approximately $1,451,000 and general and administrative (G&A) expenses of approximately $2,613,000. Operating expenses for the same period in 2018 consisted of R&D expenses of approximately $471,000, and G&A expenses of approximately $1,403,000.
R&D expenses for the three months ended March 31, 2019, were approximately $1,451,000, an increase of approximately $980,000 or 208 percent from total R&D expenses for the three months ended March 31, 2018 of approximately $471,000. The increase in R&D expense is attributed to salaries, stock-based compensation, and clinical trial expenses associated with our Endoxifen program. Stock-based compensation expense increased approximately $668,000 in 2019 resulting from the cancellation of stock options. There were no option cancellations in the comparable period in 2018. We expect our R&D expenses to increase throughout 2019 as we commence additional Phase 2 clinical studies of Endoxifen, continue the clinical trial of Fulvestrant administered via our intraductal technology and continue the development of other indications and therapeutics, including CAR-T and immunotherapies administered via our intraductal technologies.
G&A expenses were approximately $2,613,000 for the three months ended March 31, 2019, an increase of approximately $1,210,000, or 86 percent from the total G&A expenses for the three months ended March 31, 2018, of approximately $1,403,000. G&A expenses consist primarily of personnel and related benefit costs, facilities, professional services, insurance, and public company related expenses. The increase in G&A expenses for the quarter ended March 31, 2019, is mainly attributed to an increase in stock-based compensation expense due to the cancellation of 2018 options of approximately $1,074,000, payroll expenses resulting from salary increases, and increased legal and professional consulting expenses over the prior year.
As of March 31, 2019, Atossa had approximately $19.6 million in cash and cash equivalents and working capital of approximately $19.3 million.
About Atossa Genetics
Atossa Genetics Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit www.atossagenetics.com.
Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with any variation between preliminary and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa’s products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others with respect to fulvestrant, such as patent rights, potential market sizes for Atossa’s drugs under development and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form10-K and 10-Q, each as amended and supplemented from time to time.
Atossa Genetics Company Contact:
Atossa Genetics Inc.
Kyle Guse, CFO and General Counsel
Office: 866 893-4927
Investor Relations Contact:
377 Oak Street
Garden City, NY 11530
Source: Atossa Genetics Inc.
ATOSSA GENETICS INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
|As of March 31,||As of December 31,|
|Cash and cash equivalents||$||19,568,247||$||10,380,493|
|Research and development tax rebate receivable||237,856||518,098|
|Other current assets||27,957||30,942|
|Total current assets||20,779,528||11,549,366|
|Furniture and equipment, net||48,212||54,487|
|Intangible assets, net||91,667||99,375|
|Liabilities and Stockholders’ Equity|
|Stock-based compensation liability||1,410,025|
|Other current liabilities||9,863||39,939|
|Total current liabilities||1,491,141||2,915,436|
|Long term liabilities|
|Lease liability long term||37,397|
|Commitments and contingencies (note 11)|
|Preferred stock – $0.001 par value; 10,000,000 shares authorized, consisting of Series B convertible preferred stock- $0.001 par value; 702 and 2,379 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively||1||2|
|Additional paid-in capital- Series B convertible preferred stock||701,999||2,378,997|
|Common stock – $0.18 par value; 175,000,000 shares authorized, and 9,122,171 and 5,846,552 shares issued and outstanding, as of March 31, 2019 and December 31, 2018, respectively||1,641,979||1,052,372|
|Additional paid-in capital||98,056,781||82,204,902|
|Total Stockholders’ Equity||19,496,190||8,805,010|
|Total Liabilities and Stockholders’ Equity||$||21,024,728||$||11,720,446|
ATOSSA GENETICS INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
|For the Three Months Ended March 31,|
|Research and development||$||1,451,236||$||470,976|
|General and administrative||2,613,093||1,403,465|
|Total operating expenses||4,064,329||1,874,441|
|Other income (expense)||(8,978||)||59|
|Loss before income taxes||(4,073,307||)||(1,874,382||)|
|Loss per common share – basic and diluted||$||(0.62||)||$||(8.48||)|
|Weighted average shares outstanding – basic and diluted||6,565,514||220,996|